Pancreatic Cancer: Increasing Prevalence of Pancreatic Cancer is Expected to Boost The Market Growth During The Forecast Period 2022-2030

Pune, India, December, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global pancreatic cancer market.

Market Highlights

The Pancreatic Cancer Market is anticipated to reach USD 2,430.43 Million by 2030 at 7.40% CAGR during the forecast period 2022-2030

There are two major types of pancreatic cancer, endocrine pancreas cancer and exocrine pancreas cancer. The patient with pancreatic cancer are more susceptible to jaundice, weight loss, diabetes, or pain in the stomach area or back. The mortality is increasing with the increasing prevalence of this type of cancer many countries. Thus, it requires regular surveillance.

Increasing prevalence of pancreatic cancer, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology are expected to fuel the market during the forecast period. However, high cost of the treatment may slow the market growth during the period 2022-2030.

Regional Analysis

The Americas dominate the global pancreatic cancer market owing to the presence of huge patient population with cancer, high healthcare spending, and increasing government support for research & development.  

Europe holds the second largest share of the global pancreatic cancer market as result of increasing focus of various government agencies on the treatment of diseases such as pancreatic cancer. Moreover, the growing public awareness about pancreatic cancer is likely to boost the European market.

Asia Pacific is the fastest growing market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development are projected to drive the market in China and India.

The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Segmentation

The global pancreatic cancer market is segmented on the basis of types, treatment, and end user. On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others. On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is sub-segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is further segmented into tyrosine kinase inhibitors and monoclonal antibodies. The hormone therapy is segmented into estrogen-receptor modulators, aromatase inhibitors, and others. On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.

Key Players

Some of key the players in the market are Pharmacyte Biotech Inc. (U.S.), OncoGenex Pharmaceuticals Inc. (U.S.), Oncolytics Biotech (Canada), Diffusion Pharmaceuticals (U.S.), Polaris Pharmaceuticals, Inc. (U.S.), Sun BioPharma, Inc. (U.S.), Midatech Pharma PLC (U.K.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Amgen, Inc. (U.S.), Novartis International AG (U.S.), Clovis Oncology (U.S.) and others.

Explore In-depth Details: Pancreatic Cancer Market Research Report